Systemic listeriosis with adalimumab therapy

J Clin Rheumatol. 2009 Oct;15(7):369-70. doi: 10.1097/RHU.0b013e3181bf93cd.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy
  • Female
  • Humans
  • Immunity, Innate / physiology
  • Incidence
  • Listeria monocytogenes*
  • Listeriosis / epidemiology*
  • Middle Aged
  • Risk Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab